Astellas Pharma (4503) Stock Overview
Manufactures, markets, imports, and exports pharmaceuticals in Japan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 5/6 |
4503 Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Astellas Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥2,283.00 |
| 52 Week High | JP¥2,717.00 |
| 52 Week Low | JP¥1,343.50 |
| Beta | 0.084 |
| 1 Month Change | 2.28% |
| 3 Month Change | -12.24% |
| 1 Year Change | 59.76% |
| 3 Year Change | 2.42% |
| 5 Year Change | 20.92% |
| Change since IPO | 288.27% |
Recent News & Updates
Narrative Update • May 24
4503: Rising Bladder Cancer Setback Risks Will Likely Pressure Future Returns
Astellas Pharma's analyst price target has shifted from a fair value of ¥1,500 to about ¥1,670 as analysts factor in a higher assumed discount rate, softer revenue and profit expectations, and a higher future P/E multiple in their updated models. What's in the News Astellas plans to present new data across its oncology portfolio at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago, including a 3.5-year follow up from the Phase 3 EV-302 study of enfortumab vedotin plus pembrolizumab in previously untreated locally advanced or metastatic urothelial cancer, along with multiple prostate cancer and vasomotor symptom studies.
Narrative Update • May 02
4503: Bladder Cancer Progress And Updated Guidance Will Shape Fairly Balanced Outlook
Analysts have slightly reduced their fair value estimate for Astellas Pharma from about ¥2,407 to about ¥2,396, citing updated assumptions that include a softer revenue outlook, a higher projected profit margin, and a lower future P/E multiple. What's in the News Astellas and Pfizer reported positive Phase 3 EV-304 data for PADCEV (enfortumab vedotin) plus Keytruda (pembrolizumab) in muscle invasive bladder cancer, with the regimen linked to a 47% lower risk of tumor recurrence, progression or death and a 35% lower risk of death compared with standard chemotherapy, along with a higher pathological complete response rate and no new safety signals (Key Developments).Analysis Article • Apr 30
Astellas Pharma Inc. (TSE:4503) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?
Astellas Pharma Inc. ( TSE:4503 ) shareholders are probably feeling a little disappointed, since its shares fell 7.8...Recent updates
Narrative Update • May 24
4503: Rising Bladder Cancer Setback Risks Will Likely Pressure Future Returns
Astellas Pharma's analyst price target has shifted from a fair value of ¥1,500 to about ¥1,670 as analysts factor in a higher assumed discount rate, softer revenue and profit expectations, and a higher future P/E multiple in their updated models. What's in the News Astellas plans to present new data across its oncology portfolio at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago, including a 3.5-year follow up from the Phase 3 EV-302 study of enfortumab vedotin plus pembrolizumab in previously untreated locally advanced or metastatic urothelial cancer, along with multiple prostate cancer and vasomotor symptom studies.Narrative Update • May 02
4503: Bladder Cancer Progress And Updated Guidance Will Shape Fairly Balanced Outlook
Analysts have slightly reduced their fair value estimate for Astellas Pharma from about ¥2,407 to about ¥2,396, citing updated assumptions that include a softer revenue outlook, a higher projected profit margin, and a lower future P/E multiple. What's in the News Astellas and Pfizer reported positive Phase 3 EV-304 data for PADCEV (enfortumab vedotin) plus Keytruda (pembrolizumab) in muscle invasive bladder cancer, with the regimen linked to a 47% lower risk of tumor recurrence, progression or death and a 35% lower risk of death compared with standard chemotherapy, along with a higher pathological complete response rate and no new safety signals (Key Developments).Analysis Article • Apr 30
Astellas Pharma Inc. (TSE:4503) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?
Astellas Pharma Inc. ( TSE:4503 ) shareholders are probably feeling a little disappointed, since its shares fell 7.8...Narrative Update • Apr 17
4503: Bladder Cancer Data And Guidance Will Temper Risks From Weaker Legacy Portfolio
Analysts have nudged their fair value estimate for Astellas Pharma higher from ¥2,100 to about ¥2,407, citing updated assumptions for revenue trends, profit margins, and a slightly lower future P/E multiple. What's in the News Astellas and HOVON reported that the Phase 3 HOVON 156 / AMLSG 28-18 / PASHA study of XOSPATA (gilteritinib) versus midostaurin-based treatment in newly diagnosed FLT3-mutated acute myeloid leukemia did not meet its primary overall survival endpoint, with Astellas indicating it expects a minor impact on financial results for the fiscal year ending March 31, 2026 (Key Developments).
Narrative Update • Apr 02
4503: Future Oncology Pipeline And Partnerships Will Support Upside Potential
The analyst price target for Astellas Pharma has been revised from ¥2,700 to ¥2,950, with analysts citing updated assumptions for revenue growth, profit margins, and a higher future P/E multiple as key drivers behind the change. What's in the News Phase 3 HOVON 156 / AMLSG 28-18 / PASHA trial of XOSPATA (gilteritinib) in newly diagnosed FLT3-mutated acute myeloid leukemia did not meet its primary overall survival endpoint, and Astellas plans a full data review and expects only a minor impact on fiscal 2026 results.Narrative Update • Mar 19
4503: Trial Setbacks And Weaker Margins Will Likely Pressure Future Returns
Analysts have kept Astellas Pharma's fair value estimate steady at ¥1,500, while slightly adjusting assumptions for discount rate, revenue growth, profit margin and future P/E to reflect updated views on the company’s risk profile and earnings power, without changing the overall price target level. What's in the News Phase 3 HOVON 156 / AMLSG 28-18 / PASHA trial of XOSPATA (gilteritinib) in newly diagnosed FLT3-mutated acute myeloid leukemia did not meet its primary overall survival endpoint.Narrative Update • Mar 05
4503: Bladder Cancer Pipeline Dependence Will Increase Execution Risk Versus Weakening Revenue Outlook
Astellas Pharma's analyst price target has been adjusted from ¥1,938 to ¥2,100, with analysts pointing to updated assumptions around a slightly higher discount rate, softer revenue growth, a modestly stronger profit margin and a higher future P/E multiple to support the new view. What's in the News Pfizer and Astellas reported positive Phase 3 EV-304 results for PADCEV in combination with Keytruda in muscle invasive bladder cancer.Narrative Update • Feb 19
4503: Revised Earnings Outlook And Clinical Progress Will Support Balanced Future Upside
Analysts have adjusted their view on Astellas Pharma, raising the price target from ¥2,400 to ¥2,700, citing revised assumptions for the discount rate, revenue growth, profit margin, and future P/E. What's in the News Astellas revised its consolidated earnings guidance for the fiscal year ending March 31, 2026, now forecasting core revenue of ¥2,100,000 million, operating profit of ¥520,000 million, profit for the year of ¥385,000 million, and basic EPS of ¥214.95, with similar revisions on a full basis.Analysis Article • Feb 08
Astellas Pharma Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Astellas Pharma Inc. ( TSE:4503 ) defied analyst predictions to release its quarterly results, which were ahead of...Narrative Update • Feb 05
4503: Elevated Earnings Outlook Will Likely Mask Higher Long Term Margin Risks
Analysts have increased their fair value estimate for Astellas Pharma from ¥1,300 to ¥1,500, citing updated assumptions that include a revised revenue growth profile, higher projected profit margins, and a lower anticipated future P/E multiple. What's in the News Astellas raised its consolidated earnings guidance for the fiscal year ending March 31, 2026, now forecasting core revenue of ¥2,100,000 million, operating profit of ¥520,000 million, profit for the year of ¥385,000 million, and basic EPS of ¥214.95, supported by XTANDI and mirabegron products and foreign exchange effects (Key Developments).Analysis Article • Feb 05
Astellas Pharma (TSE:4503) Has Announced A Dividend Of ¥39.00
The board of Astellas Pharma Inc. ( TSE:4503 ) has announced that it will pay a dividend of ¥39.00 per share on the 3rd...Narrative Update • Jan 22
4503: Rising Bladder Cancer Reliance Will Increase Execution Risk Versus Softer Revenue Outlook
Analysts have nudged their fair value estimate for Astellas Pharma up from ¥1,884.62 to ¥1,938.46, citing updated assumptions around slightly softer revenue growth, a modestly higher profit margin, and a small adjustment to the future P/E multiple. What's in the News Sanofi is reported to be preparing a higher bid for Ocular Therapeutix, which keeps attention on deal activity in ophthalmology and broader specialty pharma (Investor's Business Daily).Analysis Article • Jan 19
Astellas Pharma's (TSE:4503) Dividend Will Be ¥39.00
The board of Astellas Pharma Inc. ( TSE:4503 ) has announced that it will pay a dividend on the 3rd of June, with...Narrative Update • Jan 07
4503: Rising Bladder Cancer Pipeline Reliance Will Increase Execution And Partnering Risks
Analysts have modestly raised their fair value estimate for Astellas Pharma from ¥1,792.14 to ¥1,884.62, citing updated assumptions around slightly softer revenue contraction, a higher profit margin outlook, and a small adjustment to the future P/E multiple. What's in the News The U.S. FDA approved PADCEV in combination with Keytruda as perioperative treatment for adult patients with muscle invasive bladder cancer who are ineligible for cisplatin chemotherapy.Analysis Article • Jan 05
Astellas Pharma's (TSE:4503) Dividend Will Be ¥39.00
Astellas Pharma Inc. ( TSE:4503 ) will pay a dividend of ¥39.00 on the 3rd of June. This makes the dividend yield 3.7...Analysis Article • Dec 17
Astellas Pharma (TSE:4503) Will Pay A Dividend Of ¥39.00
The board of Astellas Pharma Inc. ( TSE:4503 ) has announced that it will pay a dividend of ¥39.00 per share on the 3rd...Narrative Update • Dec 14
4503: Early Veeva CRM Adoption Will Support Margin Expansion And Upside Potential
Analysts have nudged their price target on Astellas Pharma higher from ¥2,200 to ¥2,400, citing the company’s role among leading pharma adopters of Veeva’s upgraded CRM platform and a modestly improved long term profit margin outlook, despite slightly softer revenue growth assumptions. Analyst Commentary Bullish analysts point to Astellas Pharma’s early adoption of Veeva’s Vault CRM as a key validation of its digital commercial strategy, aligning the company with a growing roster of large global biopharma peers migrating to the upgraded platform.Analysis Article • Dec 03
Astellas Pharma (TSE:4503) Will Pay A Dividend Of ¥39.00
Astellas Pharma Inc. ( TSE:4503 ) has announced that it will pay a dividend of ¥39.00 per share on the 3rd of June...Narrative Update • Nov 29
4503: Major Partner Platform Commitments Will Shape Competitive Positioning And Execution Risks
Analysts have slightly raised their price target for Astellas Pharma to ¥1,792.14 from ¥1,774.29. They cite continued incremental commitments from major industry partners as a supportive factor for the company's outlook.Narrative Update • Nov 15
4503: Digital Transformation Commitments Will Drive Operational Efficiency And Execution Risk Ahead
Astellas Pharma's fair value target has been raised slightly from ¥1,753 to ¥1,774. This reflects analysts' expectations of improved revenue and margin trends in light of a renewed commitment to digital transformation within the sector.Analysis Article • Nov 07
Astellas Pharma's (TSE:4503) Earnings May Just Be The Starting Point
When companies post strong earnings, the stock generally performs well, just like Astellas Pharma Inc.'s ( TSE:4503...Analysis Article • Nov 03
Astellas Pharma Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
As you might know, Astellas Pharma Inc. ( TSE:4503 ) just kicked off its latest half-yearly results with some very...Narrative Update • Nov 01
4503: Digital CRM Adoption And Margin Pressures Will Shape Medium-Term Performance
Analysts have revised their price target for Astellas Pharma to ¥1,752.86, citing a more cautious outlook on revenue growth and margin pressures. This update reflects recent industry research and changes in competitive dynamics.Narrative Update • Oct 17
Oncology And Rare Diseases Trends Will Unlock Global Potential
Astellas Pharma's analyst price target has increased slightly from ¥1,749.29 to ¥1,752.86. Analysts cite ongoing partnerships with industry leaders and an improved outlook on core platform adoption as contributing factors.Narrative Update • Oct 03
Oncology And Rare Diseases Trends Will Unlock Global Potential
Analysts have raised their price target for Astellas Pharma from ¥1,725 to ¥1,749, citing steady fundamentals and ongoing industry commitments. These points were highlighted in recent sector developments.Analysis Article • Sep 19
Astellas Pharma's (TSE:4503) Upcoming Dividend Will Be Larger Than Last Year's
Astellas Pharma Inc. ( TSE:4503 ) has announced that it will be increasing its dividend from last year's comparable...Narrative Update • Sep 18
Oncology And Rare Diseases Trends Will Unlock Global Potential
Despite a further decline in consensus revenue growth forecasts, Astellas Pharma’s analyst price target inched up from ¥1708 to ¥1725, reflecting only a marginal increase in perceived fair value. What's in the News Positive Phase 3 results for PADCEV (enfortumab vedotin) plus KEYTRUDA (pembrolizumab) in muscle-invasive bladder cancer (MIBC) patients ineligible for cisplatin; significant improvement in event-free and overall survival compared to surgery alone, with consistent safety profiles.Narrative Update • Aug 27
Oncology And Rare Diseases Trends Will Unlock Global Potential
Despite a notable improvement in consensus revenue growth forecasts, Astellas Pharma’s fair value was revised only slightly lower, with the analyst price target decreasing marginally from ¥1711 to ¥1692. What's in the News Positive Phase 3 EV-303 trial results for PADCEV (enfortumab vedotin) plus KEYTRUDA (pembrolizumab) in muscle-invasive bladder cancer show clinically meaningful improvements in event-free and overall survival versus surgery alone.Analysis Article • Aug 12
Astellas Pharma's (TSE:4503) Upcoming Dividend Will Be Larger Than Last Year's
Astellas Pharma Inc. ( TSE:4503 ) has announced that it will be increasing its dividend from last year's comparable...Analysis Article • Aug 01
Astellas Pharma Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Astellas Pharma Inc. ( TSE:4503 ) just released its latest quarterly results and things are looking bullish. The...Analysis Article • Jul 24
Astellas Pharma (TSE:4503) Is Increasing Its Dividend To ¥39.00
Astellas Pharma Inc. ( TSE:4503 ) has announced that it will be increasing its dividend from last year's comparable...Analysis Article • Jul 10
Astellas Pharma (TSE:4503) Is Paying Out A Larger Dividend Than Last Year
Astellas Pharma Inc. ( TSE:4503 ) has announced that it will be increasing its dividend from last year's comparable...Analysis Article • Jun 20
Astellas Pharma Inc.'s (TSE:4503) P/E Is On The Mark
With a price-to-earnings (or "P/E") ratio of 47.8x Astellas Pharma Inc. ( TSE:4503 ) may be sending very bearish...Shareholder Returns
| 4503 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | 0.6% | -0.3% | 1.9% |
| 1Y | 59.8% | 12.5% | 41.5% |
Return vs Industry: 4503 exceeded the JP Pharmaceuticals industry which returned 12.5% over the past year.
Return vs Market: 4503 exceeded the JP Market which returned 41.5% over the past year.
Price Volatility
| 4503 volatility | |
|---|---|
| 4503 Average Weekly Movement | 5.4% |
| Pharmaceuticals Industry Average Movement | 6.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in JP Market | 9.6% |
| 10% least volatile stocks in JP Market | 2.5% |
Stable Share Price: 4503 has not had significant price volatility in the past 3 months compared to the JP market.
Volatility Over Time: 4503's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1923 | 13,643 | Naoki Okamura | www.astellas.com |
Astellas Pharma Inc. manufactures, markets, imports, and exports pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric cancer; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also provides VEOZAH, a treatment for vasomotor symptoms due to menopause; IZERVAY, a treatment for geographic atrophy secondary to age-related macular degeneration; EVRENZO, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressant.
Astellas Pharma Inc. Fundamentals Summary
| 4503 fundamental statistics | |
|---|---|
| Market cap | JP¥4.09t |
| Earnings (TTM) | JP¥291.54b |
| Revenue (TTM) | JP¥2.14t |
14.0x
P/E Ratio1.9x
P/S RatioIs 4503 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4503 income statement (TTM) | |
|---|---|
| Revenue | JP¥2.14t |
| Cost of Revenue | JP¥408.43b |
| Gross Profit | JP¥1.73t |
| Other Expenses | JP¥1.44t |
| Earnings | JP¥291.54b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 162.73 |
| Gross Margin | 80.91% |
| Net Profit Margin | 13.63% |
| Debt/Equity Ratio | 30.9% |
How did 4503 perform over the long term?
See historical performance and comparisonDividends
3.5%
Current Dividend Yield48%
Payout RatioDoes 4503 pay a reliable dividends?
See 4503 dividend history and benchmarks| Astellas Pharma dividend dates | |
|---|---|
| Ex Dividend Date | Mar 30 2026 |
| Dividend Pay Date | Jun 03 2026 |
| Days until Ex dividend | 62 days |
| Days until Dividend pay date | 3 days |
Does 4503 pay a reliable dividends?
See 4503 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/30 06:55 |
| End of Day Share Price | 2026/05/29 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Astellas Pharma Inc. is covered by 24 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Atsushi Seki | Barclays |
| Miki Sogi | Bernstein |
| Koichi Mamegano | BofA Global Research |